StockNews.com assumed coverage on shares of Advaxis (OTCMKTS:ADXS – Get Rating) in a report published on Monday. The firm issued a sell rating on the biotechnology company's stock.
Advaxis Price Performance
Shares of Advaxis stock opened at $1.79 on Monday. The firm has a market cap of $3.25 million, a price-to-earnings ratio of -0.20 and a beta of 2.44. Advaxis has a 52-week low of $1.00 and a 52-week high of $11.18. The stock has a 50-day simple moving average of $1.73 and a 200-day simple moving average of $1.68.
Get Advaxis alerts:Advaxis Company Profile
(Get Rating)
Advaxis, Inc is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.
Read More
- Get a free copy of the StockNews.com research report on Advaxis (ADXS)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey's General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.